Pfizer and Crown to develop treatments for Asian cancers
Pfizer and US-based drug discovery company Crown Bioscience have agreed to research and develop novel therapeutics for Asian cancers.
Pfizer and US-based drug discovery company Crown Bioscience have agreed to research and develop novel therapeutics for Asian cancers.
Under the terms of this agreement, Crown will receive an upfront payment and research funding, as well as milestone payments based on the achievement of preclinical and clinical goals.
The companies will work together to discover multiple candidates for clinical development. The research will take place at Crown's new research facility in Taicang, near Shanghai, China.
"We believe we can capitalise on the oncology expertise of Crown and enhance our ability to bring novel therapeutics to the marketplace that will benefit cancer patients in Asia," said Neil Gibson, chief scientific officer of Pfizer's Oncology Research Unit.
